Discuss collagen-stimulating injectable options with Dr. Berra Aydın. The choice depends on your concern, the treatment area and the characteristics of each product.
Compare the images, descriptions and listed prices. Your doctor recommends the product and amount after assessing you and the intended treatment area.
A poly-L-lactic acid injectable in Galderma’s collagen-focused treatment range.
The local product presentation, amount and planned appointments are confirmed at consultation.
A hybrid injectable combining hyaluronic acid and calcium hydroxylapatite. Discuss its intended facial treatment areas, expected changes and product-specific aftercare with the doctor.
A poly-L-lactic acid option with different formulations for face and body. Your doctor confirms the appropriate presentation, treatment area and quantity for your individual plan.
Official manufacturer logo shown. The exact product presentation and quantity are confirmed before treatment.
A polycaprolactone-based injectable in the Ellansé range. Product selection, treatment area and follow-up are assessed individually.
The price list does not identify an S, M, L or E variant. The image does not define the formulation included in this price.
Prices are from the NEXJA medical price list. Confirm the quantity, appointments and total before proceeding. Manufacturer pack size does not automatically equal your treatment quantity.
Biostimulatory injectables are not a single interchangeable category. Products may use poly-L-lactic acid, calcium hydroxylapatite or polycaprolactone, sometimes combined with a gel carrier or hyaluronic acid. Some effects develop gradually and treatment plans may involve more than one appointment. Product choice, application area and aftercare require medical assessment. These options should not be assumed to have the same reversibility as hyaluronic acid fillers.
Discuss this treatment on WhatsApp ↗Review facial changes, past procedures and whether this category fits your goals.
PLLA, CaHA and PCL products differ in behaviour, reversibility and aftercare. Discuss the exact option.
Agree on appointments, review timing and total cost. A listed price does not automatically cover a full course.
Discuss your goals, the proposed treatment and your questions before deciding.
View the doctor’s Instagram ↗Prepare for your consultation.
This category includes products with a collagen-stimulating component, sometimes alongside a gel that provides an earlier effect. It is not one standard injection. Material, intended treatment area and expected changes differ, so the plan should identify the exact product rather than simply promise “more collagen”.
The NEXJA list gives Sculptra at €650, HArmonyCa at €550, Lanluma at €650 and Ellansé at €550, with VAT included. It does not define the vial quantity or a complete course. Confirm the presentation, amount, appointments and full quotation before booking.
Sculptra and Lanluma are PLLA options. HArmonyCa combines hyaluronic acid with CaHA, while Ellansé is PCL-based. These materials behave differently and have distinct instructions. Their names, prices and pack images do not establish that they are interchangeable for a particular area.
No. A conventional hyaluronic acid filler and a product with a collagen-stimulating component differ in material and treatment behaviour. Some collagen-focused options aim for changes that develop over time. Compare expected onset, reversibility, aftercare and the overall plan as well as the desired appearance.
Do not assume a product containing PLLA, PCL or CaHA can be dissolved like hyaluronic acid filler. Even a hybrid product has more than one component to consider. Discuss reversibility and how complications would be managed before consenting to treatment.
Sculptra is planned around a gradual response rather than judging a final outcome on the day of injection. Its manufacturer describes treatment over several appointments for many patients. The doctor should explain the expected review timeline for your plan; early fullness is not proof of the final collagen-related result.
The number depends on the chosen product and your assessment. There is no shared course length for all four options. Ask for the proposed amount at each visit, intervals, reassessment points and total price, rather than treating one catalogue entry as a complete programme.
No. A product offered for one concern should not automatically be used in another area. Confirm the exact formulation, intended use and local instructions with the doctor. In particular, do not assume a collagen-stimulating product is an alternative to a lip or under-eye filler.
Discuss your medical history, allergies, previous fillers and any history of unusual scarring or treatment complications. Your goals may be better addressed with another treatment or no treatment. Brand preference alone cannot establish suitability for a collagen-stimulating injectable.
Potential problems include injection-site discomfort, bruising, swelling and lumps or nodules; the full risk profile depends on the product. Filler-related vascular complications also need discussion. Ask how to recognise a problem, who to contact and how review or treatment of a complication would be arranged.
No. Aftercare is product-specific, including whether massage is advised. Follow the written instructions for the treatment actually performed instead of borrowing advice for another brand. Confirm guidance about skincare, activities and when to return for assessment.
It may require more than one visit, so agree on the sequence before booking travel around it. Ask NEXJA to arrange a consultation with Dr. Berra Aydın and clarify review options, future appointments and total cost. A single visit or a particular result cannot be promised from the listed price alone.
Swelling, bruising and tenderness can occur after injectable treatments. Risks depend on the product and treatment area. Fillers can rarely cause serious vascular complications, including tissue damage or vision problems. Unusual or increasing pain, skin colour changes or visual symptoms need urgent medical assessment.
Prepared 23 October 2026. Clinical review is pending. Manufacturer information may refer to another market; local product information applies.
Tell us what you have in mind. We’ll help arrange your consultation.